Replies to post #221746 on Biotech Values

[DewDiligence]

(RVNC)—3Q18 worldwide Botox sales=$879.7M, +14% YoY (-6% QoQ*):

http://phx.corporate-ir.net/External.File?t=1&item=VHlwZT0yfFBhcmVudElEPTUyNzU1Mjd8Q2hpbGRJRD03MDEwNzI=

• US therapeutic: $407.4M (+10 YoY)
• US cosmetic: $216.0M (+14% YoY)
• Ex-US therapeutic: $92.9 (+17 YoY in constant currency)
• Ex-US cosmetic: $163.4M (+33% YoY in constant currency)

All told, 71% of Botox sales were in the US, where the therapeutic/cosmetic split was 65/35; 29% of Botox sales were ex-US, where the therapeutic/cosmetic split was 36/64.

*The 3Q18 decline relative to 2Q18 was expected; Botox is seasonally stronger in the second and fourth quarters of the calendar year.

[DewDiligence]

For what it’s worth, Reuters mentions RVNC in its newswire on AGN’s 3Q18 results:

https://finance.yahoo.com/news/botox-sales-power-allergans-profit-122924497.html